Revelation Biosciences reported a net loss of $15.0 million for fiscal year 2024, compared to a $0.1 million loss in 2023. Revenue remained at zero as the company continued development of its proprietary Gemini formulation programs. Research and development expenses were $3.5 million, while general and administrative costs totaled $4.4 million. The company ended the year with $6.5 million in cash and cash equivalents.The company made progress advancing its clinical pipeline, including GEM-AKI for acute kidney injury prevention, GEM-CKD for chronic kidney disease treatment, and GEM-PSI for post-surgical infection prevention. Key developments included completing a Phase 1 clinical study showing significant increases in anti-inflammatory cytokines, and initiating a Phase 1b study in CKD patients in January 2025.During 2024, Revelation strengthened its financial position through multiple offerings and warrant exercises, raising net proceeds of $12.8 million. The company implemented a 1-for-16 reverse stock split in January 2025 and regained Nasdaq compliance in February 2025. Management indicates current cash will not sustain operations for 12 months, raising substantial doubt about going concern.

Revelation Biosciences reported a net loss of $15.0 million for fiscal year 2024, compared to a $0.1 million loss in 2023. Revenue remained at zero as the company continued development of its proprietary Gemini formulation programs. Research and development expenses were $3.5 million, while general and administrative costs totaled $4.4 million. The company ended the year with $6.5 million in cash and cash equivalents.The company made progress advancing its clinical pipeline, including GEM-AKI for acute kidney injury prevention, GEM-CKD for chronic kidney disease treatment, and GEM-PSI for post-surgical infection prevention. Key developments included completing a Phase 1 clinical study showing significant increases in anti-inflammatory cytokines, and initiating a Phase 1b study in CKD patients in January 2025.During 2024, Revelation strengthened its financial position through multiple offerings and warrant exercises, raising net proceeds of $12.8 million. The company implemented a 1-for-16 reverse stock split in January 2025 and regained Nasdaq compliance in February 2025. Management indicates current cash will not sustain operations for 12 months, raising substantial doubt about going concern.